Drug Trial Radar · NCT00410761
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
331
Actual
Start
Nov 23, 2006
Primary completion
Jul 31, 2009
Study completion Jul 26, 2024
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 13, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Conditions
- Thyroid Cancer
Interventions
ZD6474 (Vandetanib)Drug
once daily oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival(PFS)Time frame: RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.
Locations
127 sites in 24 countries. Site status is shown where the registry gives one.
Investigational Site Number 3
Little Rock, Arkansas
University Arkansas Site Number : 3
Little Rock, Arkansas
Investigational Site Number 8
San Francisco, California
USCF / Mt Zion Medical Center Site Number : 8
San Francisco, California
Investigational Site Number 9
Aurora, Colorado
University Of Colorado Health Sciences Center Site Number : 9
Aurora, Colorado
Investigational Site Number 11
New Haven, Connecticut
Yale University School Medicine Site Number : 11
New Haven, Connecticut
Investigational Site Number 15
Jacksonville, Florida
Mayo Clinic- Site Number : 15
Jacksonville, Florida
Investigational Site Number 18
Chicago, Illinois
The University Of Chicago Site Number : 18
Chicago, Illinois
Investigational Site Number 17
Lexington, Kentucky
The University Of Kentucky Site Number : 17
Lexington, Kentucky
Dana Farber Cancer Institute Site Number : 2
Boston, Massachusetts
Investigational Site Number 2
Boston, Massachusetts
Investigational Site Number 7
Detroit, Michigan
Wayne State University / Harper Hospital Site Number : 7
Detroit, Michigan
Investigational Site Number 14
Rochester, Minnesota
Mayo Clinic- Site Number : 14
Rochester, Minnesota
Investigational Site Number 10
St Louis, Missouri
Washington University School Of Med Site Number : 10
St Louis, Missouri
Investigational Site Number 6
Cincinnati, Ohio
University Of Cincinnati Site Number : 6
Cincinnati, Ohio
Investigational Site Number 22
Portland, Oregon
Oregon Health & Science University- Site Number : 22
Portland, Oregon
Investigational Site Number 19
Charleston, South Carolina
Medical University of South Carolina- Site Number : 19
Charleston, South Carolina
Anderson Cancer Center Site Number : 13
Houston, Texas
Investigational Site Number 13
Houston, Texas
Fletcher Allen Health Care Site Number : 21
Burlington, Vermont
Investigational Site Number 21
Burlington, Vermont
Investigational Site Number 1001
St Leonards, Australia
Investigational Site Number 1901
Vienna, Austria
Investigational Site Number : 1901
Vienna, Austria
Investigational Site Number : 1101
Anderlecht, Belgium
Investigational Site Number 1101
Brussels, Belgium
Investigational Site Number 1102
Leuven, Belgium
Investigational Site Number : 1102
Leuven, Belgium
Investigational Site Number 2301
Porto Alegre, Brazil
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.